Psychedelic medicine is moving fast. Faster than regulation. Faster than standardization. And in many ways, faster than the data itself.

In this episode, we explore what psychedelics are teaching us about practicing medicine under uncertainty. From the rapid rise of training programs and self-identified experts, to the tension between lived experience, emerging science, and clinical responsibility, this conversation looks beyond hype or skepticism.

Drawing on psychedelic research, integrative medicine, and historical parallels like psychotherapy, biofeedback, and hormone therapy, this episode asks a deeper question: how do we determine expertise in an emerging field? And what does responsible leadership look like when certainty would be premature?

This is an invitation to steward a powerful field with humility, honesty, and care.

Psychedelics are teachers, let’s let them teach us.

Our understanding of how psychedelics work has evolved in meaningful ways over the past several years. While earlier neuroscience frameworks helped move the field forward, newer research has added important nuance and depth to how we interpret brain imaging, network behavior, and subjective experience.

In this episode of The Trip Lab, I offer a refresh on psychedelic neuroscience, focusing on key updates from the past four years and how they change the story we tell about what’s happening in the brain and the body during psychedelic states.

We explore:

• How the Default Mode Network is better understood as dynamically modulated rather than simply reduced
• Why psychedelic brain states are best described as time-varying and network-based rather than static
• How neural entropy is now understood as increased flexibility through relaxed constraints
• Why brain, body, and context are inseparable in shaping psychedelic experiences and outcomes

This episode is designed to update earlier explanations, clarify what has changed, and highlight why the newer neuroscience offers a more accurate and more interesting framework for understanding psychedelic effects.

Microdosing has gone mainstream and is often described as a tool for creativity, mood, productivity, and emotional healing. But what does the science actually say?

In this episode of The Trip Lab, I take an evidence-based look at microdosing psychedelics. We explore what microdosing is, how it differs from full-dose psychedelic therapy, and the proposed neurobiological mechanisms that have been suggested in the literature. I review what current clinical trials and placebo-controlled studies are showing so far, and where the data remains limited or inconclusive.

A central focus of this episode is the placebo response. Rather than treating placebo as “fake” or irrelevant, I explain how expectancy, meaning, belief, and context produce real, measurable changes in the brain and body. We discuss why placebo responses are especially strong in interventions involving consciousness, perception, and mental health, and how this helps explain why many people genuinely feel better with microdosing even when objective outcomes are mixed.

This episode separates enthusiasm from evidence, explores where microdosing may be helpful, where claims get overstretched, and what questions researchers are actively trying to answer next.

If you’re curious about microdosing and want a grounded, medically informed perspective that respects both science and lived experience, this conversation is for you.